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Sir,
We read with great interest the work published by Shin et al (2015),
which highlights the potential relevance of circulating cell-free miRNAs
as biomarkers for the detection of triple-negative breast cancer (TNBC).
Of importance, the authors identified three miRNAs (miR-16, miR-21
and miR-199-5p) as potential diagnostic biomarkers for TNBC. The
information provided is of interest as the identification of miRNA
signatures for TNBC, as well as for other types of cancer (Calin and
Croce, 2006), is of increasing relevance. However, we found some
worthwhile issues that need to be discussed. The authors’ conclusions
seem to be based only on results obtained from a univariate analysis
performed for each of the above mentioned miRNAs. Specifically they
performed a receiver–operator characteristics (ROC) curve to assess their
ability to discriminate TNBC patients from healthy controls. Results
showed a considerable discriminatory performance for each of the three
miRNAs. Although the authors reported in the statistical analysis section
the following sentence: ‘Multivariate logistic regression model was
established and leave one-out cross validation to find the best logistic
model’, no results were provided in multivariate terms. The lack of
assessment of the more intriguing level of diagnostic accuracy achievable
by combining the three miRNAs in a composite score is a relevant
drawback of the paper. This topic, that actually represents one of the
most critical steps in developing a miRNA-based signature in cancer
research, implies some methodological considerations directly related to
the multivariate regression models theory (Harrell, 2001). Multivariate
regression models allowing simultaneous association of miRNAs and
predictors with clinical outcome, such as logistic regression for presence/
absence of disease, are common building blocks of biomarker-based risk
prediction tools. It should be considered that in such scenario the
number of observations is not generally of the order of magnitude greater
than the number of variables. Results from the multivariate regression
models may thus be affected by the small number of events per variable
(Verderio, 2012). As a consequence, the model may produce over-
optimistic estimation of the combined area under the curve (AUC) on
the original data, but fails when applied in an independent data set
(Verderio et al, 2010). In addition, to better generate prediction and
generalisation to new data, the model should be defined according to the
principle of parsimony, which is essential in discriminating the structural
part (signal) of empirical data from the idiosyncratic (noise) one
(Vandekerckhove et al, 2015). Although different approaches had been
described in the literature to find the optimal linear combination of
putative miRNAs to maximise the AUC (Su and Liu, 1993; Pepe and
Thompson, 2000; Kang et al, 2013; Yan et al, 2015), we believe that it is
urgent to delineate a procedure that is methodologically as robust as
flexible to cover this fundamental step.
To this end, we are developing a comprehensive procedure that,
starting from a set of potential miRNAs, identifies a more powerful
and parsimonious composite score. Briefly, the best combination
of the potential miRNAs is reached by resorting to penalised
maximum likelihood estimation (PMLE) regression methods
(Harrell, 2001) that can provide more reliable results in the presence
of large numbers of input variables. A more parsimonious final model
was then obtained using a step-down procedure as suggested by
Ambler et al (2002).
As example, for illustration purpose only, we applied our procedure in
a similar context of Shin et al (2015), to data on circulating miRNAs in
plasma from 20 hepatocellular carcinoma (HCC) patients and 20 healthy
donors (GSE50013) retrieved from the Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/gds). By applying our NqA
algorithm (Verderio et al, 2014), four miRNAs were identified as
potential diagnostic biomarkers for HCC. As reported in Table 1, the
AUC value observed for each of these miRNAs ranged from 0.739 to
0.841. Interestingly, by combining these miRNAs with the PMLE
approach, we observed a sensible increment of the predictive capability
with an AUC value of 0.953. In addition, we obtained a more
parsimonious model based only on three miRNAs (AUC¼ 0.923)
without the loss of discriminatory power. A similar AUC value
(AUC¼ 0.920) was observed by applying the least absolute shrinkage
and selection operator (LASSO) method (Tibshirani, 1996). Notably, the
two approaches retained the same three miRNAs.
In conclusion, this example shows that a more appropriate way to get
the information for the evaluation of miRNAs as biomarkers could be
interpreting their predictive role in a multivariate fashion or following
Collins et al (2015), that ‘Prediction is inherently multivariable’.
This suggests the need of resorting to statistical procedures, generally
based on advanced methods, in order to properly embrace the
complexity of the data with the ultimate aim of better predicting the
presence/absence of disease.
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hsa-miR-1274B-002884 0.761 (0.606; 0.916)
hsa-miR-483-5p-4395449 0.841 (0.722; 0.961)
MammU6-4395470 0.811 (0.677; 0.946)
U6 snRNA-001973 0.739 (0.585; 0.893)
Multivariate logistic models
Full PMLEa 0.953 (0.893; 1.000)
Reduced PMLEa 0.923 (0.845; 1.000)
LASSOb 0.920 (0.841; 0.999)
aPenalised maximum likelihood estimation.
bLeast absolute shrinkage and selection operator.
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